학술논문
GFc7 as a Smart Growth Nanofactor for ex vivo Expansion and Cryoprotection of Humans' Hematopoietic Stem Cells
ORIGINAL RESEARCH
ORIGINAL RESEARCH
Document Type
Academic Journal
Author
Source
International Journal of Nanomedicine. August 31, 2020, Vol. 15, p6263, 15 p.
Subject
Language
English
ISSN
1178-2013
Abstract
Introduction Hematopoietic stem cells (HSCs) were first used more than half a century ago and the United States Food and Drug Administration (FDA) have approved HSCs transplant for use against [...]
Background: Nowadays, smart synthesized nanostructures have attracted wide attention in the field of stem cell nanotechnology due to their effect on different properties of stem cells. Methods: GFc7 growth nanofactor was synthesized based on nanochelating technology as an iron-containing copper chelator nanocomplex. The effect of this nanocomplex on the expansion and differentiation of hematopoietic stem cells (HSCs) as well as its performance as a cryoprotectant was evaluated in the present study. Results: The results showed that the absolute count of [CD34.sup.+]. and [CD34.sup.+][CD38.sup.-] cells on days 4, 7, 10 and 13; the percentage of lactate dehydrogenase enzyme on the same days and [CD34.sup.+]CXCR4 population on day 10 were significantly increased when they were treated with GFc7 growth nanofactor in a fetal bovine serum (FBS)-free medium. This medium also led to delayed differentiation in HSCs. One noticeable result was that [CD34..sup.+][CD38.sup.-] cells cultured in an FBS medium were immediately differentiated into [CD34.sup.+][CD38.sup.+] cells, while [CD34.sup.+][CD38.sup.-] cells treated with GFc7 growth nanofactor in FBS medium did not show such an immediate significant differentiation. De-freezing GFc7-treated [CD34.sup.+] cells, which were already frozen according to cord blood bank protocols, showed a higher percentage of cell viability and a larger number of colonies according to colony-forming cell assay as compared to control. Conclusion: It can be claimed that treating HSCs with GFc7 growth nanofactor leads to quality and quantity improvement of HSCs, both in terms of expansion in vitro and freezing and de-freezing processes. Keywords: expansion, GFc7, human hematopoietic stem cells, nanocomplex, nanochelating technology
Background: Nowadays, smart synthesized nanostructures have attracted wide attention in the field of stem cell nanotechnology due to their effect on different properties of stem cells. Methods: GFc7 growth nanofactor was synthesized based on nanochelating technology as an iron-containing copper chelator nanocomplex. The effect of this nanocomplex on the expansion and differentiation of hematopoietic stem cells (HSCs) as well as its performance as a cryoprotectant was evaluated in the present study. Results: The results showed that the absolute count of [CD34.sup.+]. and [CD34.sup.+][CD38.sup.-] cells on days 4, 7, 10 and 13; the percentage of lactate dehydrogenase enzyme on the same days and [CD34.sup.+]CXCR4 population on day 10 were significantly increased when they were treated with GFc7 growth nanofactor in a fetal bovine serum (FBS)-free medium. This medium also led to delayed differentiation in HSCs. One noticeable result was that [CD34..sup.+][CD38.sup.-] cells cultured in an FBS medium were immediately differentiated into [CD34.sup.+][CD38.sup.+] cells, while [CD34.sup.+][CD38.sup.-] cells treated with GFc7 growth nanofactor in FBS medium did not show such an immediate significant differentiation. De-freezing GFc7-treated [CD34.sup.+] cells, which were already frozen according to cord blood bank protocols, showed a higher percentage of cell viability and a larger number of colonies according to colony-forming cell assay as compared to control. Conclusion: It can be claimed that treating HSCs with GFc7 growth nanofactor leads to quality and quantity improvement of HSCs, both in terms of expansion in vitro and freezing and de-freezing processes. Keywords: expansion, GFc7, human hematopoietic stem cells, nanocomplex, nanochelating technology